These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511 [TBL] [Abstract][Full Text] [Related]
34. Fosfomycin--investigation of a possible new route of administration of an old drug. A case study. Cree M; Stacey S; Graham N; Wainwright C J Cyst Fibros; 2007 May; 6(3):244-6. PubMed ID: 17055346 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
36. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of resistant Pseudomonas aeruginosa with elective and rescue intravenous antibiotic regimens in children with cystic fibrosis. Smyth E; David TJ; Patel L; Ashcroft P; Sanyal D; Vyas J Int J Antimicrob Agents; 2005 Jul; 26(1):95-6. PubMed ID: 15970432 [No Abstract] [Full Text] [Related]
38. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis]. Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396 [TBL] [Abstract][Full Text] [Related]